# 2025-13047: FDA Gauges If 'Real Cost' Campaign Scares Teens Straight

2025-13047, Agency Information Collection Activities; Proposed Collection; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-07-14, effective 60 days for public comment in response to the notice. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-13047
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-13047
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 31229
- Published: 2025-07-14
- Effective: 60 days for public comment in response to the notice.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Gauges If 'Real Cost' Campaign Scares Teens Straight

## Summary

The FDA wants your thoughts on continuing their study about how well the Real Cost Campaign helps people make healthier choices. This study affects teens and young adults by tracking their habits over time. They’re asking for comments within 60 days—no new costs, just a chance to share your opinion!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the extension of the currently approved collection "The Real Cost Campaign Outcomes Evaluation Study: Cohort 3."

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-13047 on federalregister.gov](https://www.federalregister.gov/documents/2025/07/14/2025-13047/agency-information-collection-activities-proposed-collection-comment-request-the-real-cost-campaign)
- [2025-13047 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-07-14/pdf/2025-13047.pdf)

## Related
- [Previous: 2025-13046, Determination of Regulatory Review Period for Purposes of Patent Extension; ABR…](https://policyrisk.com/federal-register/2025-13046)
- [Next: 2025-13048, Determination of Regulatory Review Period for Purposes of Patent Extension; HEM…](https://policyrisk.com/federal-register/2025-13048)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-13047 (as of 2026-06-08).